A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
The purpose of this study is to characterize the long-term safety of lisocabtagene maraleucel (liso-cel), focusing on patients treated in the chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities
Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL)
BIOLOGICAL: Lisocabtagene maraleucel
Adverse events (AEs), Up to 15 years
Complete remission rate (CRR, Up to 15 years|Overall response rate (ORR), Up to 15 years|Progression-free survival (PFS), Up to 15 years|Overall survival (OS), Up to 15 years
The purpose of this study is to characterize the long-term safety of lisocabtagene maraleucel (liso-cel), focusing on patients treated in the chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities